Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) Director Kim Tsuchimoto sold 1,199 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $70.10, for a total value of $84,049.90. Following the completion of the transaction, the director directly owned 1,199 shares of the company’s stock, valued at $84,049.90. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Stock Up 4.2%
Monopar Therapeutics stock traded up $2.92 during mid-day trading on Wednesday, hitting $72.81. The company had a trading volume of 189,611 shares, compared to its average volume of 143,006. The stock has a market cap of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62. Monopar Therapeutics Inc. has a 1 year low of $50.07 and a 1 year high of $124.82. The business has a fifty day moving average of $88.66 and a 200 day moving average of $77.40.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Equities analysts anticipate that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the stock. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Barclays restated an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. BTIG Research raised their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $122.00.
Check Out Our Latest Stock Report on MNPR
Hedge Funds Weigh In On Monopar Therapeutics
A number of institutional investors have recently modified their holdings of MNPR. Your Advocates Ltd. LLP purchased a new stake in Monopar Therapeutics in the 1st quarter valued at $183,000. The Manufacturers Life Insurance Company acquired a new stake in Monopar Therapeutics during the 1st quarter worth $250,000. Sei Investments Co. grew its position in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the last quarter. Bank of America Corp DE grew its position in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in Monopar Therapeutics in the first quarter valued at $3,458,000. 1.83% of the stock is owned by institutional investors and hedge funds.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.
Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.
Read More
- Five stocks we like better than Monopar Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
